{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:10:14Z","timestamp":1791263414493,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,2,16]],"date-time":"2010-02-16T00:00:00Z","timestamp":1266278400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1038\/sj.bjc.6605529","type":"journal-article","created":{"date-parts":[[2010,2,16]],"date-time":"2010-02-16T21:07:35Z","timestamp":1266354455000},"page":"810-814","source":"Crossref","is-referenced-by-count":80,"title":["The management and outcome of women with post-hydatidiform mole \u2018low-risk\u2019 gestational trophoblastic neoplasia, but hCG levels in excess of 100\u2009000\u2009IU\u2009l\u22121"],"prefix":"10.1038","volume":"102","author":[{"given":"S","family":"McGrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P M","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Seckl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,16]]},"reference":[{"key":"BF6605529_CR1","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/1097-0142(197609)38:3<1373::AID-CNCR2820380342>3.0.CO;2-E","volume":"38","author":"KD Bagshawe","year":"1976","unstructured":"Bagshawe KD (1976) Risk and prognostic factors in trophoblastic neoplasia. Cancer 38: 1373\u20131385","journal-title":"Cancer"},{"key":"BF6605529_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1471-0528.1989.tb03318.x","volume":"96","author":"KD Bagshawe","year":"1989","unstructured":"Bagshawe KD, Dent J, Newlands ES, Begent RG, Rustin GJ (1989) The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 96: 795\u2013802","journal-title":"Br J Obstet Gynaecol"},{"key":"BF6605529_CR3","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/1097-0142(19821115)50:10<2024::AID-CNCR2820501008>3.0.CO;2-4","volume":"50","author":"RS Berkowitz","year":"1982","unstructured":"Berkowitz RS, Goldstein DP, Bernstein MR (1982) Methotrexate with citrovorum factor rescue as primary therapy for gestational trophoblastic disease. Cancer 50: 2024\u20132027","journal-title":"Cancer"},{"key":"BF6605529_CR4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/030089168707300317","volume":"73","author":"G Bolis","year":"1987","unstructured":"Bolis G, Colombo N, Epis A, Mangili G, Vassena L, Vergadoro F, Belloni C (1987) Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumor. Tumori 73: 309\u2013313","journal-title":"Tumori"},{"key":"BF6605529_CR5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0090-8258(88)80029-5","volume":"31","author":"G Bolis","year":"1988","unstructured":"Bolis G, Bonazzi C, Landoni F, Mangili G, Vergadoro F, Zanaboni F, Mangioni C (1988) EMA\/CO regimen in high-risk gestational trophoblastic tumor (GTT). Gynecol Oncol 31: 439\u2013444","journal-title":"Gynecol Oncol"},{"key":"BF6605529_CR6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0959-8049(98)00059-8","volume":"34","author":"M Bower","year":"1998","unstructured":"Bower M, Rustin GJ, Newlands ES, Holden L, Short D, Foskett M, Bagshawe KD (1998) Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years. Eur J Cancer 34: 1204\u20131207","journal-title":"Eur J Cancer"},{"key":"BF6605529_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ygyno.2004.04.018","volume":"94","author":"LM Chen","year":"2004","unstructured":"Chen LM, Lengyel ER, Bethan Powell C (2004) Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecol Oncol 94: 204\u2013207","journal-title":"Gynecol Oncol"},{"key":"BF6605529_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1479-828X.2005.00366.x","volume":"45","author":"MM Gilani","year":"2005","unstructured":"Gilani MM, Yarandi F, Eftekhar Z, Hanjani P (2005) Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust N Z J Obstet Gynaecol 45: 161\u2013164","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"BF6605529_CR9","first-page":"461","volume":"14","author":"NC Gleeson","year":"1993","unstructured":"Gleeson NC, Finan MA, Fiorica JV, Robert WS, Hoffman MS, Wilson J (1993) Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 14: 461\u2013465","journal-title":"Eur J Gynaecol Oncol"},{"key":"BF6605529_CR10","first-page":"643","volume":"49","author":"SJ Kim","year":"2004","unstructured":"Kim SJ, Lee C, Kwon SY, Na YJ, Oh YK, Kim CJ (2004) Studying changes in the incidence, diagnosis and management of GTD: the South Korean model. J Reprod Med 49: 643\u2013654","journal-title":"J Reprod Med"},{"key":"BF6605529_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1046\/j.1525-1438.2000.00002.x","volume":"10","author":"EI Kohorn","year":"2000","unstructured":"Kohorn EI, Goldstein DP, Hancock BW, Kim SJ, Lurain JR, Newlands E, Soper JT, Wong LC (2000) Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Health Organization for trophoblastic neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society. Int J Gynaecol Cancer 10: 84\u201388","journal-title":"Int J Gynaecol Cancer"},{"key":"BF6605529_CR12","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1200\/JCO.2002.07.166","volume":"20","author":"IA McNeish","year":"2002","unstructured":"McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, Newlands ES (2002) Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 20: 1838\u20131844","journal-title":"J Clin Oncol"},{"key":"BF6605529_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1471-0528.1991.tb10369.x","volume":"98","author":"ES Newlands","year":"1991","unstructured":"Newlands ES, Bagshawe KD, Begent RH, Rustin GJ, Holden L (1991) Results with the EMA\/CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) regimen in high-risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 98: 550\u2013557","journal-title":"Br J Obstet Gynaecol"},{"key":"BF6605529_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1200\/JCO.2000.18.4.854","volume":"18","author":"ES Newlands","year":"2000","unstructured":"Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJS (2000) Etoposide and cisplatin\/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA\/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol 18: 854\u2013859","journal-title":"J Clin Oncol"},{"key":"BF6605529_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CCO.0b013e3282dc94e5","volume":"19","author":"S Ngan","year":"2007","unstructured":"Ngan S, Seckl MJ (2007) Gestational trophoblastic neoplasia management: an update. Curr Opin Oncol 19: 486\u2013491","journal-title":"Curr Opin Oncol"},{"key":"BF6605529_CR16","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ygyno.2007.11.036","volume":"108","author":"R Osborne","year":"2008","unstructured":"Osborne R, Filiaci V, Schink J, Mannel R, Provencher D, Alvarez-Secord A, Kelley J, Lage J, Schilder J, Miller D (2008) A randomized phase III trial comparing weekly parenteral methotrexate and \u2018pulse\u2019 dactinomycin as primary management for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group study. Gynecol Oncol 108: S2\u2013S3 Abstract #2","journal-title":"Gynecol Oncol"},{"key":"BF6605529_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ygyno.2004.08.045","volume":"95","author":"M Pezeshki","year":"2004","unstructured":"Pezeshki M, Hancock BW, Silcocks P, Everard JE, Coleman J, Gillespie AM, Tidy J, Coleman RE (2004) The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol Oncol 95: 423\u2013429","journal-title":"Gynecol Oncol"},{"key":"BF6605529_CR18","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1200\/JCO.1996.14.10.2769","volume":"14","author":"GJS Rustin","year":"1996","unstructured":"Rustin GJS, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Foskett M, Fuller S, Short D (1996) Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumours increases the incidence of second tumours. J Clin Oncol 14: 2769\u20132773","journal-title":"J Clin Oncol"},{"key":"BF6605529_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ygyno.2005.07.025","volume":"99","author":"P Savage","year":"2005","unstructured":"Savage P, Seckl MJ (2005) The role of repeat uterine evacuation in trophoblast disease. Gynecol Oncol 99: 251\u2013252","journal-title":"Gynecol Oncol"},{"key":"BF6605529_CR20","doi-asserted-by":"publisher","first-page":"a1193","DOI":"10.1136\/bmj.a1193","volume":"337","author":"NJ Sebire","year":"2008","unstructured":"Sebire NJ, Seckl MJ (2008) Gestational trophoblastic disease: current management of hydatidiform mole. BMJ 337: a1193","journal-title":"BMJ"},{"key":"BF6605529_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(00)02432-6","volume":"356","author":"MJ Seckl","year":"2000","unstructured":"Seckl MJ, Fisher RA, Salerno G, Rees H, Paradinas FJ, Foskett M, Newlands ES (2000) Choriocarcinoma and partial hydatidiform moles. Lancet 356: 36\u201339","journal-title":"Lancet"},{"key":"BF6605529_CR22","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1136\/ijgc-00009577-200605000-00074","volume":"16","author":"T Turan","year":"2006","unstructured":"Turan T, Karacay O, Tulunay G, Boran N, Koc S, Bozok S, Kose MF (2006) Results with EMA\/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. Int J Gynecol Cancer 16: 1432\u20131438","journal-title":"Int J Gynecol Cancer"},{"key":"BF6605529_CR23","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1093\/annonc\/mdn181","volume":"19","author":"J Wang","year":"2008","unstructured":"Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Seckl MJ (2008) Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel\/cisplatin alternating with paclitaxel\/etoposide (TP\/TE). Ann Oncol 19: 1578\u20131583","journal-title":"Ann Oncol"},{"key":"BF6605529_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ijgo.2008.05.013","volume":"103","author":"F Yarandi","year":"2008","unstructured":"Yarandi F, Eftekhar Z, Shojaei H, Kanani S, Sharifi A, Hanjani P (2008) Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J Gynaecol Obstet 103: 33\u201337","journal-title":"Int J Gynaecol Obstet"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6605529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605529","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6605529.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:43:45Z","timestamp":1684413825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6605529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,16]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["BF6605529"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6605529","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,16]]}}}